ClinicalTrials.gg
CompletedNCT00097695Updated Jun 9, 2021Results posted

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

A Phase 3 interventional study of Icatibant and Placebo in Angioedema, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Primary conditionAngioedemas, HereditaryRegistry: AngioedemaReclassifiedWhy we changed it
Registry
Angioedema — the first condition term the registry derived for this study.
ClinicalTrials.gg
Angioedemas, Hereditary
Why
  1. The study's title name Angioedemas, Hereditary, a narrower term within Angioedema.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
4th of 10
84 · median 26
Started
2004
the only one that year
Phase 3
7 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 4th largest by enrollment, is the only one that started in 2004, is one of 7 in phase 3, and was the 1st registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of Icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (HAE).

Read the detailed description

This Phase II/III study consisted of two parts: A controlled phase and An Open label extension(OLE) phase. The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy of icatibant in decreasing the time to onset of symptom relief compared with placebo for the first treated cutaneous and/or abdominal attack in randomised patients. Patients experienced a laryngeal attack were not randomised, but treated with open label icatibant according to the controlled phase procedures and assessments. The outcome of this group was to be reported descriptively. After treatment of the first attack in the controlled phase, the patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the end of the study.The OLE phase became a modified open label extension where all 56 patients who had been randomised and the last randomised patient had concluded the double-blind phase. The modified open label extension period permitted treatment for patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the double blind phase was still ongoing.

03

Conditions studied

  • Angioedema

Browse trials for

Keywords

  • Hereditary Angioedema
  • C1 inhibitor deficiency
  • HAE
  • Icatibant
  • Bradykinin antagonist
  • acute attack
  • subcutaneous
04

In context

Angioedemas, Hereditary Reclassified

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

This study's enrollment of 84 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.

Browse Angioedemas, Hereditary studies →

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Compared within Angioedemas, Hereditary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Angioedema. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 18 years;
  • Documented diagnosis of HAE Type I or II (confirmed complement 1 esterase inhibitor [C1-INH] deficiency);
  • Current edema be in the cutaneous, abdominal and/or laryngeal areas;
  • Current edema be moderate to severe according to the investigator's Symptom Score.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of angioedema other than HAE, for example, acquired angioedema (AAE);
  • Participation in a clinical trial of another medicinal product (IMP) within the past month;
  • Treatment with any pain medication since onset of the current edema attack;
  • Treatment with replacement therapy, including C1-INH products (e.g. human C1-INH preparations), less than 3 days from onset of the current edema attack;
  • Treatment with ACE inhibitors (e.g. Lotensin, Prinivil, Accupril);
  • Evidence of severe, symptomatic coronary artery disease based on medical history or screening examination;
  • Serious concomitant illnesses that the physician considers to be a for participation in the trial;
  • Pregnancy and/or breast-feeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Icatibant- Randomized

    Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.

    Drug: Icatibant

  • Placebo comparator
    Placebo-Randomized

    Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.

    Drug: Placebo

  • Experimental
    Controlled Open-label / laryngeal attack

    Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.

    Drug: Icatibant

  • Experimental
    Untreated Patients at the baseline

    Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )

    Drug: Icatibant

Interventions

  • 30 mg (3mL) subcutaneous icatibant injection in the abdominal region

    Also known as: Brand name, Firazyr®

  • DrugPlacebo

    Solution for injection, matched to study drug Single dose: 3 mL

07

What researchers measure

Primary outcomes

  1. Time to Onset of Symptom Relief (TOSR)

    The primary efficacy endpoint was TOSR assessed by the patient using a Visual Analogue Scale (VAS). The VAS is a scale used to measure intensity of each symptom of the attack at baseline and at the pre-determined time points throughout treatment period. It consists of a horizontal 10cm line, with the 0 point corresponding to a state where patient experiences no symptoms at all and the 10cm point represents the worst symptoms ever experienced by patient. The patient indicates his/her current state of symptoms by drawing a mark across the horizontal line. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the 3 primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.

    Time frame: 5 days

Secondary outcomes

  1. Time to Regression (Start of Improvement) According to Patient

    This parameter assessed the time to regression (start of improvement) of observable(visible) symptoms according to the patients. Patients were asked "Report date and time when you feel that your symptoms start to improve".

    Time frame: 5 days

  2. Time to Almost Complete Symptom Relief

    The time to almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least 3 consecutive measurements for all symptom.

    Time frame: 5 days

08

Results

Posted Dec 24, 2013

Participant flow

The Controlled Phase
Participant flow — The Controlled Phase
MilestoneRandomized -IcatibantRandomized -PlaceboControlled Open-label / Laryngeal AttackUntreated Patients at the Baseline
Started2729820
Completed232630
Not completed43520
The Open Label Extension (OLE) Phase
Participant flow — The Open Label Extension (OLE) Phase
MilestoneRandomized -IcatibantRandomized -PlaceboControlled Open-label / Laryngeal AttackUntreated Patients at the Baseline
Started2326320
Completed1011115
Not completed131525

Outcome measures

PrimaryTime to Onset of Symptom Relief (TOSR)

The primary efficacy endpoint was TOSR assessed by the patient using a Visual Analogue Scale (VAS). The VAS is a scale used to measure intensity of each symptom of the attack at baseline and at the pre-determined time points throughout treatment period. It consists of a horizontal 10cm line, with the 0 point corresponding to a state where patient experiences no symptoms at all and the 10cm point represents the worst symptoms ever experienced by patient. The patient indicates his/her current state of symptoms by drawing a mark across the horizontal line. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the 3 primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.

Time frame:
5 days
Reported as:
Median · Hours
Time to Onset of Symptom Relief (TOSR)
HoursRandomized -IcatibantRandomized -Placebo
Time to Onset of Symptom Relief (TOSR)2.5 (1.1 to 6.0)4.6 (1.8 to 10.2)
Statistical analysis
  • Randomized -Icatibant vs Randomized -Placebo · Wilcoxon version of the log-rank test · p = 0.142The Wilcoxon version of the log-rank test of SAS was used to calculate statistical significance between p- vs icatibant group and placebo group.
SecondaryTime to Regression (Start of Improvement) According to Patient

This parameter assessed the time to regression (start of improvement) of observable(visible) symptoms according to the patients. Patients were asked "Report date and time when you feel that your symptoms start to improve".

Time frame:
5 days
Reported as:
Median · Hours
Time to Regression (Start of Improvement) According to Patient
HoursRandomized -IcatibantRandomized -Placebo
Time to Regression (Start of Improvement) According to Patient0.8 (0.5 to 2.0)16.9 (3.2 to NA)
Statistical analysis
  • Randomized -Icatibant vs Randomized -Placebo · Wilcoxon version of the log-rank test · p = < 0.001The median time to onset is calculated using Kaplan-Meier methodology. The Wilcoxon version of the log-rank test of SAS is used.
SecondaryTime to Almost Complete Symptom Relief

The time to almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least 3 consecutive measurements for all symptom.

Time frame:
5 days
Reported as:
Median · Hours
Time to Almost Complete Symptom Relief
HoursRandomized Control Trial-icatibantRandomized Control Trial-placebo
Time to Almost Complete Symptom Relief8.5 (2.5 to 31.5)19.4 (10.2 to 55.7)
Statistical analysis
  • Randomized Control Trial-icatibant vs Randomized Control Trial-placebo · Wilcoxon version of the log-rank test · p = = 0.079The median time to almost complete symptom relief was calculated using Kaplan-Meier methodology.The Wilcoxon version of the log-rank test of SAS used.

Adverse events

Collected over An AE was assigned to the controlled phase if the event start date was between the first treatment of the first attack and the first treatment in the OLE phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Controlled Phase- Icatibant (Randomized Subjects )—0/27 (0%)12/27 (44.4%)
Controlled Phase- Placebo (Randomized Subjects—0/29 (0%)19/29 (65.5%)
Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack)—1/8 (12.5%)6/8 (75%)
Open Label Extension Phase- Icatibant (Previously Randomized)—3/49 (6.1%)39/49 (79.6%)
Open Label Extension -Icatibant (Subjects w/ Laryngeal Attack)—0/3 (0%)3/3 (100%)
Open Label Extension Phase(Untreated Patients at the Baseline)—0/20 (0%)17/20 (85%)
Most frequent serious events
Most frequent serious events
EventControlled Phase- Icatibant (Randomized Subjects )Controlled Phase- Placebo (Randomized SubjectsControlled Phase- Icatibant (Subjects w/ Laryngeal Attack)Open Label Extension Phase- Icatibant (Previously Randomized)Open Label Extension -Icatibant (Subjects w/ Laryngeal Attack)Open Label Extension Phase(Untreated Patients at the Baseline)
HAE attackCongenital, familial and genetic disorders0/270/291/81/490/30/20
PancreatitisGastrointestinal disorders0/270/290/81/490/30/20
Chest PainGeneral disorders0/270/290/81/490/30/20
Most frequent other events
Most frequent other events
EventControlled Phase- Icatibant (Randomized Subjects )Controlled Phase- Placebo (Randomized SubjectsControlled Phase- Icatibant (Subjects w/ Laryngeal Attack)Open Label Extension Phase- Icatibant (Previously Randomized)Open Label Extension -Icatibant (Subjects w/ Laryngeal Attack)Open Label Extension Phase(Untreated Patients at the Baseline)
Headache/MigraineNervous system disorders0/272/292/80/492/31/20
Hereditary angioedemaCongenital, familial and genetic disorders4/275/294/817/491/35/20
InfectionsInfections and infestations4/274/291/820/490/37/20
DizzinessInvestigations2/271/290/80/491/30/20
Administration site conditionsGeneral disorders3/274/290/811/491/33/20
Blood Creatine Phosphokinase IncreasedInvestigations1/270/290/81/491/32/20
NauseaGastrointestinal disorders0/273/290/82/490/30/20
Nasal CongestionRespiratory, thoracic and mediastinal disorders2/270/290/80/490/30/20
PruritusSkin and subcutaneous tissue disorders0/272/290/80/490/30/20
ContusionInjury, poisoning and procedural complications0/270/290/83/490/30/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Randomized -IcatibantRandomized -PlaceboControlled Open-label / Laryngeal AttackUntreated Patients at the BaselineTotal
Mean34.8 ± 9.8134.9 ± 11.3747.1 ± 13.8637.4 ± 11.4836.6 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Randomized -IcatibantRandomized -PlaceboControlled Open-label / Laryngeal AttackUntreated Patients at the BaselineTotal
Female162151557
Male1183527
09

Study locations

1 site
  • Georgetown University Hospital, Lombardi Cancer Center
    Washington, District of Columbia 20007-2197, United States
10

References and documents

Publications

  • Malbran A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hebert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernandez Romero DS, Lumry W. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014 Aug;177(2):544-53. doi: 10.1111/cei.12358. PubMed 24749847 ↗
  • Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anne S, Bjorkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hebert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernandez Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum In: N Engl J Med. 2010 Oct 7;363(15):1486. PubMed 20818888 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2004 to primary completion in Jul 2006, 18 months.

Results were first posted in Dec 2013, 7 years 5 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 18 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2004
First posted
Nov 29, 2004
StartActual
Dec 28, 2004
Primary completionActual
Jul 17, 2006
CompletionActual
Jul 17, 2006
Results first posted
Dec 24, 2013
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00097695
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 29, 2004
Start date
Dec 28, 2004
Primary completion
Jul 17, 2006
Completion
Jul 17, 2006
Results posted
Dec 24, 2013
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion